I missed one or two over the past three years.
At times I was willing to administer Singapore-style caning justice with my own hands. SMH many times.
That said these things are not mutually exclusive.
One can appreciate some things about him, and depreciate (despise, not like, get mildly irritated, etc.) many others.
It is not as simple a black and white choice as many espouse it to be. Being deep from within pharma and for a quite a long duration - numerous items many (dis)credit him for are complex and not a situation created/solved/destroyed by one person. He has many culpabilities but if I told you what happens in the hallways of big pharma in terms of massive screwups that never get shared with the public (one of Nader's deficits - not knowing when to stop sharing his thoughts or aspirations) you would not believe it. Companies with 10s of thousands of employees and dozens to hundreds of BLAs or sBLAs, NDAs etc. botched trials and more.
But I'm not here to defend him but rather to pose a real-life scenario where everyone engaged is operating in very dynamic and error prone environments (FDA conduct over the past 18 months is one example) that we should not fantasize even for a moment that Nader is the source of all trouble and, even worse, the 13D are the source of any comfort or salvation.
If 13D truly were interested in helping shape up the ship - they would offer a reasonable approach such as two directors or expanding BOD and placing 50% voting rights/seats with 13D directors. That, together with a coherent plan that does not portray CytoDyn to be the biggest disaster the world of biotech has ever seen would lend them credibility and support from many folks (like me with a very sizeable share count) who would be willing to force some additional accountability while sustaining respectful dialog and employing collaborative methods to address gaps while still moving forward.
A company the size of CytoDyn with 20 +- staff could be set back two years with this type of hostility. Is no one considering the effect of what comes across as all out war on the entire company? That with BOD, Nader, Kelly and one or two others, several of the few remaining leaders would run out and want nothing to do with the crowd that came to gut them? No one can just come in and resurrect a biotech after losing 30-50% of its brain trust. Not to mention any collaborative and supporting relationships from hospitals, research institutions and others.
They are not coming to help. And if they think they are - they are not qualified to help as they have absolutely no understanding how crippling such as 'swap' can be.
But I agree with you. Nader has some things to work on!
Market Data 
Markets 
AI
